2024
P-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab
Yi I, Gaspar E, Eighmy W, Roeder H, Bar N. P-377 Impact of Weekly Versus Twice Weekly Bortezomib on Rates of Peripheral Neuropathy in Combination With Lenalidomide, Dexamethasone and Daratumumab. Clinical Lymphoma Myeloma & Leukemia 2024, 24: s251. DOI: 10.1016/s2152-2650(24)02279-1.Peer-Reviewed Original Research
2020
Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma
Patel K, Parker T, Di M, Bar N, Huntington S, Giri S. Cost-Effectiveness of Once-Weekly Selinexor, Bortezomib, and Dexamethasone (SVd) Versus Twice-Weekly Bortezomib and Dexamethasone (Vd) in Relapsed or Refractory Multiple Myeloma. Blood 2020, 136: 51-52. DOI: 10.1182/blood-2020-141972.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioQuality-adjusted life yearsBest supportive careRefractory multiple myelomaMultiple myelomaSupportive careProbabilistic sensitivity analysesDisease progressionIncremental effectivenessIncremental costPost-progression therapyTwice-weekly bortezomibLarge randomized trialsProgression-free survivalUS payer perspectiveIncremental lifetime costOne-way sensitivity analysesCost-effectiveness ratioQuality of lifeCost of treatmentCost-effectiveness analysisVD progressionAnnual discount rateAdverse eventsHazard ratio